MCID: HPT014
MIFTS: 49

Hepatorenal Syndrome

Categories: Endocrine diseases, Gastrointestinal diseases, Liver diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Hepatorenal Syndrome

MalaCards integrated aliases for Hepatorenal Syndrome:

Name: Hepatorenal Syndrome 12 77 54 56 45 15 74
Hepato-Renal Syndrome 54

Classifications:



External Ids:

Disease Ontology 12 DOID:11823
ICD9CM 36 572.4
MeSH 45 D006530
NCIt 51 C113400
SNOMED-CT 69 51292008
ICD10 34 K76.7
UMLS 74 C0019212

Summaries for Hepatorenal Syndrome

NIH Rare Diseases : 54 Hepatorenal syndrome is a form of impaired kidney function that occurs in individuals with advanced chronic liver disease. As many as 40% of individuals with cirrhosis and ascites will develop hepatorenal syndrome. Symptoms may include fatigue, abdominal pain, and a general feeling of ill health (malaise). There are two distinct types of hepatorenal syndrome. Type I progresses quickly (within days), leading to kidney failure. Individuals with type I typically have dramatically reduced urine output, edema, and jaundice, and often suffer from hepatic encephalopathy. Type II progresses more slowly, over weeks or months, and the symptoms are less severe. The cause of hepatorenal syndrome is unknown. A contributing factor seems to be a narrowing of the blood vessels that connect into the kidneys. This causes a decrease in blood flow to the kidneys, impairing their function. In some cases, triggers or precipitating factors (infections, blood loss from the gastrointestinal tract, low blood pressure) are involved. Treatment is aimed at helping the liver work better and maintaining kidney function. In many cases, a liver transplant is needed. In some cases, individuals also need a kidney transplant. 

MalaCards based summary : Hepatorenal Syndrome, also known as hepato-renal syndrome, is related to infantile liver failure syndrome 1 and acute liver failure. An important gene associated with Hepatorenal Syndrome is ALB (Albumin), and among its related pathways/superpathways are FOXA2 and FOXA3 transcription factor networks and IL1 and megakaryocytes in obesity. The drugs Terlipressin and Adefovir Dipivoxil have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and testes, and related phenotypes are homeostasis/metabolism and cardiovascular system

Disease Ontology : 12 An acute kidney failure that is characterized by severe renal vasoconstriction.

Wikipedia : 77 Hepatorenal syndrome (often abbreviated HRS) is a life-threatening medical condition that consists of... more...

Related Diseases for Hepatorenal Syndrome

Diseases related to Hepatorenal Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 189)
# Related Disease Score Top Affiliating Genes
1 infantile liver failure syndrome 1 30.9 ALB F2
2 acute liver failure 30.3 ALB F2
3 hepatitis a 30.3 ALB F2
4 hepatic coma 30.2 ALB F2
5 esophageal varix 30.2 ALB F2
6 compartment syndrome 30.1 ALB F2
7 hepatopulmonary syndrome 30.1 ALB EDN1
8 portal hypertension 29.9 ALB EDN1 F2
9 obstructive jaundice 29.8 ALB EDN1 F2 REN
10 acute kidney tubular necrosis 29.7 ALB CST3 IL18 NPPA
11 eclampsia 29.6 ALB EDN1 F2 REN
12 pre-eclampsia 29.3 EDN1 F2 NPPA REN
13 liver cirrhosis 29.3 ALB AQP2 EDN1 F2 NPPA REN
14 pulmonary hypertension 29.2 ACE EDN1 NPPA REN
15 pulmonary edema 28.9 ACE EDN1 F2 NPPA REN
16 joubert syndrome with oculorenal anomalies 11.6
17 peroxisome biogenesis disorder 1a 11.3
18 liver disease 10.4
19 benign essential hypertension 10.4 ALB REN
20 kidney papillary necrosis 10.4 ALB REN
21 malignant hypertensive renal disease 10.3 EDN1 REN
22 malignant renovascular hypertension 10.3 EDN1 REN
23 antipyrine metabolism 10.3 ALB F2
24 non-a-e hepatitis 10.3 ALB F2
25 hepatitis 10.3
26 malignant secondary hypertension 10.3 EDN1 REN
27 epstein-barr virus hepatitis 10.3 ALB F2
28 perinephritis 10.3 EDN1 REN
29 fournier gangrene 10.3 ALB F2
30 abdominal tuberculosis 10.3 ALB F2
31 hepatic tuberculosis 10.3 ALB F2
32 kwashiorkor 10.3 ALB F2
33 intestinal impaction 10.3 F2 REN
34 hemorrhagic fever 10.3 ALB F2
35 renal tuberculosis 10.3 EDN1 REN
36 splenic disease 10.3 ALB F2
37 ascending cholangitis 10.3 ALB F2
38 hypersplenism 10.3 ALB F2
39 cardiac tamponade 10.3 F2 REN
40 choledocholithiasis 10.3 ALB F2
41 analbuminemia 10.3 ALB F2
42 noma 10.3 ALB IL18
43 autoimmune disease of urogenital tract 10.3 ALB F2
44 pulmonary artery disease 10.3 ALB F2
45 apnea, obstructive sleep 10.3 EDN1 REN
46 dysfibrinogenemia 10.3 ALB F2
47 loeffler syndrome 10.3 ACE ALB
48 hepatitis e 10.2 ALB F2
49 renal artery obstruction 10.2 ACE REN
50 vein disease 10.2 ALB F2

Comorbidity relations with Hepatorenal Syndrome via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alcoholic Liver Cirrhosis
Chronic Kidney Failure Deficiency Anemia
Heart Disease Hepatic Encephalopathy
Portal Hypertension

Graphical network of the top 20 diseases related to Hepatorenal Syndrome:



Diseases related to Hepatorenal Syndrome

Symptoms & Phenotypes for Hepatorenal Syndrome

MGI Mouse Phenotypes related to Hepatorenal Syndrome:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.91 ACE ALB AQP2 CST3 EDN1 F2
2 cardiovascular system MP:0005385 9.87 ACE CST3 EDN1 F2 IL18 NPPA
3 mortality/aging MP:0010768 9.76 ACE ALB AQP2 CST3 EDN1 F2
4 muscle MP:0005369 9.43 ALB CST3 EDN1 IL18 NPPA REN
5 renal/urinary system MP:0005367 9.1 ACE ALB AQP2 EDN1 NPPA REN

Drugs & Therapeutics for Hepatorenal Syndrome

Drugs for Hepatorenal Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Terlipressin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 14636-12-5 72081
2
Adefovir Dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
3
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
4
Norfloxacin Approved Phase 4 70458-96-7 4539
5
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
6
Mannitol Approved, Investigational Phase 4,Phase 3 69-65-8 453 6251
7
Tranexamic Acid Approved Phase 4 1197-18-8 5526
8
Isoleucine Approved, Investigational, Nutraceutical Phase 4 73-32-5, 443-79-8 6306
9
Adefovir Investigational Phase 4 106941-25-7
10 Vasoconstrictor Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
11 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Antiviral Agents Phase 4,Phase 2,Not Applicable
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Nucleic Acid Synthesis Inhibitors Phase 4
15 Anti-Retroviral Agents Phase 4
16 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Reverse Transcriptase Inhibitors Phase 4
18 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Not Applicable
19 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Not Applicable
20 Topoisomerase Inhibitors Phase 4
21 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
22 Cytochrome P-450 Enzyme Inhibitors Phase 4
23 Hemostatics Phase 4,Not Applicable
24 Coagulants Phase 4
25 Antifibrinolytic Agents Phase 4
26 leucine Phase 4
27 valine Phase 4
28 Anticoagulants Phase 4,Not Applicable
29 Blood Substitutes Phase 4
30 Dextrans Phase 4
31 Plasma Substitutes Phase 4
32
Pentoxifylline Approved, Investigational Phase 3,Not Applicable 6493-05-6 4740
33
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-24-8 5755
34
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Not Applicable 302-25-0
35
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 83-43-2 6741
36
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Not Applicable 2921-57-5
37
Propranolol Approved, Investigational Phase 3,Not Applicable 525-66-6 4946
38
Midodrine Approved Phase 2, Phase 3,Phase 3,Not Applicable 133163-28-7, 42794-76-3 4195
39
Octreotide Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 83150-76-9 6400441 383414
40
Rifaximin Approved, Investigational Phase 3,Phase 2,Not Applicable 80621-81-4 6436173 46783403
41
Norepinephrine Approved Phase 3,Phase 2,Early Phase 1,Not Applicable 51-41-2 439260
42
Dopamine Approved Phase 2, Phase 3 62-31-7, 51-61-6 681
43
Furosemide Approved, Vet_approved Phase 2, Phase 3 54-31-9 3440
44
Tolvaptan Approved Phase 2, Phase 3 150683-30-0 216237
45
Spironolactone Approved Phase 2, Phase 3 52-01-7, 1952-01-7 5833
46
Sargramostim Approved, Investigational Phase 2, Phase 3,Not Applicable 123774-72-1, 83869-56-1
47
Lenograstim Approved, Investigational Phase 2, Phase 3,Not Applicable 135968-09-1
48
Basiliximab Approved, Investigational Phase 3 152923-56-3, 179045-86-4
49
Mycophenolic acid Approved Phase 3 24280-93-1 446541
50
Sirolimus Approved, Investigational Phase 3 53123-88-9 46835353 6436030 5284616

Interventional clinical trials:

(show top 50) (show all 106)
# Name Status NCT ID Phase Drugs
1 Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response Unknown status NCT01530711 Phase 4 Terlipressin and albumin
2 The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure Unknown status NCT02489864 Phase 4 Terlipressin
3 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
4 Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis Completed NCT00359853 Phase 4 Oral norfloxacin
5 Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention Completed NCT01542801 Phase 4 Norfloxacin;ciprofloxacin
6 Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding Recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
7 Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C Recruiting NCT03633279 Phase 4 Branched chain amino acid;Placebo
8 Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin Suspended NCT00287664 Phase 4 terlipressin
9 The INFECIR-2 Albumin Prevention Study Terminated NCT02034279 Phase 4 Albumin
10 Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis Terminated NCT00570960 Phase 4 Dextran 70
11 Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome Unknown status NCT00742690 Phase 2, Phase 3 terlipressin given by intravenous boluses and albumin;terlipressin given by continuous intravenous infusion and albumin
12 Short-term Survival in Patients With Severe Alcoholic Hepatitis Treated With Steroid Versus Pentoxifylline Unknown status NCT01455337 Phase 3 pentoxifylline;Prednisolone
13 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Unknown status NCT02649335 Phase 3 Propranolol
14 Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1 Completed NCT00089570 Phase 3 terlipressin;Placebo
15 Noradrenalin vs Terlipressin in Hepatorenal Syndrome Completed NCT00370253 Phase 3 Terlipressin;Noradrenalin
16 A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin Completed NCT01143246 Phase 3 Terlipressin;Placebo
17 TYPE 2 HEPATORENAL SYNDROME Completed NCT01637454 Phase 3 Noradrenaline;Terlipressin
18 The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction Completed NCT00240045 Phase 2, Phase 3 Midodrine, albumin, octreotide LAR;midodrine, octreotide, albumin
19 Terlipressin in Septic Shock in Cirrhosis Completed NCT00628160 Phase 2, Phase 3 Terlipressin;alpha adrenergic drugs
20 Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites Completed NCT02173288 Phase 2, Phase 3 Standard medical therapy;Tolvaptan;Midodrine
21 Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. Completed NCT00502086 Phase 3
22 Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study Completed NCT02451033 Phase 2, Phase 3 standard medical therapy;G-CSF;Growth Hormone
23 CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment Completed NCT00604357 Phase 3 anti-CD 25 mAb, Sirolimus, MMF
24 Double-blind Randomized Controlled Trial in Severe Alcoholic Hepatitis Completed NCT01214226 Phase 3 Pentoxifylline;placebo
25 Effects of Propofol on Oxidative Stress and Liver Regeneration After Partial Hepatectomy Completed NCT00219856 Phase 3 Propofol;Penthotal;Desflurane
26 Terlipressin Infusion Alone Vs Terlipressin With Noradrenaline Infusion In The Treatment of Hepatorenal Syndrome Type 1 Recruiting NCT03822091 Phase 3 Terlipressin;Terlipressin and Noradrenaline
27 Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1. Recruiting NCT03455322 Phase 2, Phase 3 norepinephrine versus midodrine & octreotide
28 A Study To Confirm Efficacy and Safety of Terlipressin in HRS Type 1 Recruiting NCT02770716 Phase 3 Terlipressin acetate
29 Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction Recruiting NCT01453218 Phase 3 ATeGe-Fresenius
30 Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone Recruiting NCT02281929 Phase 3 Amoxicillin;Placebo;Prednisolone
31 Hepatic Venous Pressure Gradient-guided Versus Standard Beta-blocker Therapy in Primary Prevention of Variceal Bleeding Recruiting NCT01618890 Phase 3
32 Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites Recruiting NCT03069131 Phase 3 Rifaximin
33 Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome Terminated NCT00742339 Phase 2, Phase 3 Terlipressin plus albumin;Midodrine plus octreotide plus human albumin
34 Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE Withdrawn NCT00787436 Phase 3 Thalidomide
35 Low-dose Albumin Solution in SBP: a Randomized Double-blind Pilot Study Unknown status NCT00852800 Phase 2 Albumin;Albumin
36 Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis Unknown status NCT02116556 Phase 2 Prednisone;Rifaximin
37 UC-MSC Infusion for HBV-Related Acute-on-Chronic Liver Failure Unknown status NCT02812121 Phase 2 umbilical cord blood mesenchymal stem cells
38 Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Hydrocortisone on Renal and Haemodynamic Function Unknown status NCT00657306 Phase 2 hydrocortisone;dextrose solution 5%
39 Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients Completed NCT01436500 Phase 2 Ifetroban Injection;Placebo
40 A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1 Completed NCT01373606 Phase 1, Phase 2 Terlipressin
41 Single Pass Albumin Dialysis in Patients With Cirrhosis Completed NCT00764049 Phase 1, Phase 2
42 A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis Completed NCT00562783 Phase 2 Vitaliver;Placebo
43 The Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure Completed NCT01254994 Phase 2 entecavir;Traditional comprehensive medical treatment
44 Midodrine and Albumin for Cirrhotic Patients With Functional Renal Impairment Completed NCT01133795 Phase 2 Midodrine plus Albumin
45 Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH) Completed NCT02854631 Phase 2 Selonsertib;Prednisolone;Placebo
46 Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure Recruiting NCT03860155 Phase 1, Phase 2
47 Safety and Efficacy of Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure Not yet recruiting NCT03863002 Phase 1, Phase 2
48 Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure Withdrawn NCT01587222 Phase 2 Albumin;Midodrine;Octreotide
49 A Study to Evaluate the Reactogenicity, Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' HBV (Hepatitis B Virus) Viral Vector Vaccines and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection Not yet recruiting NCT03866187 Phase 1 Placebo
50 A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome Terminated NCT01906307 Phase 1 LJPC-501

Search NIH Clinical Center for Hepatorenal Syndrome

Cochrane evidence based reviews: hepatorenal syndrome

Genetic Tests for Hepatorenal Syndrome

Anatomical Context for Hepatorenal Syndrome

MalaCards organs/tissues related to Hepatorenal Syndrome:

42
Liver, Kidney, Testes, Bone, Skin, Bone Marrow, Skeletal Muscle

Publications for Hepatorenal Syndrome

Articles related to Hepatorenal Syndrome:

(show top 50) (show all 735)
# Title Authors Year
1
Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis. ( 30684079 )
2019
2
The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records. ( 30724682 )
2019
3
Role of Probiotic Mixture with and Without Green Tea Extract in Prevention of Hepatorenal Syndrome in Rat Model. ( 30796765 )
2019
4
Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome. ( 30887050 )
2019
5
Terlipressin-Induced Peripheral Cyanosis in a Patient with Liver Cirrhosis and Hepatorenal Syndrome. ( 30600312 )
2019
6
Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome. ( 30606404 )
2019
7
Response to Terlipressin in Hepatorenal Syndrome: Predict to Prognosticate! ( 29914639 )
2018
8
Systemic hemodynamic response to terlipressin predicts development of hepatorenal syndrome and survival in advanced cirrhosis. ( 29432366 )
2018
9
Development of an automated phenotyping algorithm for hepatorenal syndrome. ( 29530803 )
2018
10
Hepatorenal syndrome: the clinical impact of vasoactive therapy. ( 29258378 )
2018
11
Oxidative stress, NOx/l-arginine ratio and glutathione/glutathione S-transferase ratio as predictors of 'sterile inflammation' in patients with alcoholic cirrhosis and hepatorenal syndrome type II. ( 29658815 )
2018
12
Disruption of renal arginine metabolism promotes kidney injury in hepatorenal syndrome. ( 29631342 )
2018
13
Predictors of Response to Terlipressin in Hepatorenal Syndrome. ( 29551736 )
2018
14
When Should We Stop Treatment With Terlipressin and Albumin for Patients With Hepatorenal Syndrome? ( 29684461 )
2018
15
A novel scoring model for predicting mortality risk in patients with cirrhosis and hepatorenal syndrome. ( 29634664 )
2018
16
Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial. ( 29469046 )
2018
17
Circulating miR-21, miR-210 and miR-146a as potential biomarkers to differentiate acute tubular necrosis from hepatorenal syndrome in patients with liver cirrhosis: a pilot study. ( 29303765 )
2018
18
Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. ( 29422242 )
2018
19
Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. ( 29391267 )
2018
20
Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis. ( 29668606 )
2018
21
Hepatorenal syndrome in the era of acute kidney injury. ( 29845739 )
2018
22
Clinical Outcomes after Liver Transplantation for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis. ( 29992152 )
2018
23
Hepatorenal Syndrome: Physiology, Diagnosis and Management. ( 30087522 )
2018
24
High expression of type I inositol 1,4,5-trisphosphate receptor in the kidney of rats with hepatorenal syndrome. ( 30090007 )
2018
25
Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study. ( 30178092 )
2018
26
Hepatorenal syndrome. ( 30213935 )
2018
27
Hepatorenal syndrome. ( 30213943 )
2018
28
Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data. ( 30223273 )
2018
29
A systematic review and meta-analysis of treatment for hepatorenal syndrome with traditional Chinese medicine. ( 30225390 )
2018
30
Noradrenaline for Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure: Hope Remains! ( 30229972 )
2018
31
Noradrenaline for reverting hepatorenal syndrome: a prospective, observational, single-center study. ( 30271187 )
2018
32
Author Correction: Hepatorenal syndrome. ( 30323303 )
2018
33
Terlipressin for the treatment of hepatorenal syndrome: An overview of current evidence. ( 30474439 )
2018
34
Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. ( 30597709 )
2018
35
Clinical utility of urinary neutrophil gelatinase-associated lipocalin and serum cystatin C in a cohort of liver cirrhosis patients with renal dysfunction: a challenge in the diagnosis of hepatorenal syndrome. ( 30601335 )
2018
36
Evaluation of the criteria of hepatorenal syndrome type of acute kidney injury in patients with cirrhosis admitted to ICU. ( 30621473 )
2018
37
Editorial: tackling hepatorenal syndrome-terlipressin for all, or time for a stratified approach? ( 28621082 )
2017
38
Terlipressin versus other vasoactive drugs for hepatorenal syndrome. ( 28953318 )
2017
39
Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis. ( 28991106 )
2017
40
New Developments in Hepatorenal Syndrome. ( 28602971 )
2017
41
Bile Cast Nephropathy in Patients with Acute Kidney Injury Due to Hepatorenal Syndrome: A Postmortem Kidney Biopsy Study. ( 28660146 )
2017
42
Protective Effects of the Third Generation Vasodilatory I9eta - Blocker Nebivolol against D-Galactosamine - Induced Hepatorenal Syndrome in Rats. ( 29362613 )
2017
43
Induction of renal artery hyperresponsiveness by alpha1-adrenoceptor in hepatorenal syndrome. ( 29312606 )
2017
44
Noradrenaline as an alternative medical treatment to terlipressin in the management of hepatorenal syndrome type 1. ( 29054321 )
2017
45
Association of arginine vasopressin receptor 1a gene polymorphisms with hepatorenal syndrome. ( 28420919 )
2017
46
Hepatorenal syndrome: role of the transjugular intrahepatic stent shunt in real life practice. ( 29151800 )
2017
47
Hepatorenal Syndrome ( 28613606 )
2017
48
Comparative efficacy of vasoconstrictor therapies for type 1 hepatorenal syndrome: a network meta-analysis. ( 28708431 )
2017
49
Portopulmonary hypertension and hepatorenal syndrome. Two faces of the same coin. ( 28583409 )
2017
50
Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. ( 28403995 )
2017

Variations for Hepatorenal Syndrome

Expression for Hepatorenal Syndrome

Search GEO for disease gene expression data for Hepatorenal Syndrome.

Pathways for Hepatorenal Syndrome

Pathways related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.8 ALB F2
2 10.35 F2 IL18
3 9.98 ACE CST3

GO Terms for Hepatorenal Syndrome

Cellular components related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 ACE ALB CST3 EDN1 F2 IL18
2 endoplasmic reticulum lumen GO:0005788 9.33 ALB CST3 F2
3 extracellular space GO:0005615 9.23 ACE ALB CST3 EDN1 F2 IL18

Biological processes related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.62 EDN1 F2 IL18 NPPA
2 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.49 EDN1 IL18
3 negative regulation of proteolysis GO:0045861 9.48 CST3 F2
4 regulation of vasoconstriction GO:0019229 9.46 ACE EDN1
5 positive regulation of heart rate GO:0010460 9.43 EDN1 NPPA
6 regulation of blood vessel size GO:0050880 9.4 EDN1 NPPA
7 response to muscle stretch GO:0035994 9.37 EDN1 NPPA
8 amyloid-beta metabolic process GO:0050435 9.26 ACE REN
9 cellular protein metabolic process GO:0044267 9.26 ALB CST3 F2 NPPA
10 angiotensin maturation GO:0002003 9.16 ACE REN
11 regulation of blood pressure GO:0008217 8.92 ACE EDN1 NPPA REN

Molecular functions related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 8.92 EDN1 F2 NPPA REN

Sources for Hepatorenal Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....